Dr. Randall T. Huling, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Mississippi School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 679
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: University of Mississippi School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
MS license 09846
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospitals of Memphis Memphis, TN
- Baptist Memorial Hospital Memphis, TN
- Baptist Memorial Hospital Desoto Southaven, MS
- Methodist Healthcare - Olive Branch Hospital Olive Branch, MS
Medical groups
- Olive Branch Family Medical Center (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 679
- Services billed
- 9,275
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 2,374 | 291 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 870 | 258 |
| Established patient office or other outpatient visit, 30-39 minutes | 444 | 350 |
| Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | 370 | 180 |
| Insertion of needle into vein for collection of blood sample | 364 | 282 |
| Injection, dexamethasone sodium phosphate, 1 mg | 243 | 55 |
| Administration of influenza virus vaccine | 221 | 219 |
| Influenza vaccine split virus, preservative free | 214 | 212 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 188 | 31 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 187 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 12 payments worth $229 in total to this clinician.
| Novo Nordisk Inc | $51.88 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $46.65 |
| Pfizer Inc. | $37.80 |
| AbbVie Inc. | $29.40 |
| Ardelyx, Inc. | $29.11 |
| Boston Scientific Corporation | $22.75 |
| Phathom Pharmaceuticals, Inc. | $11.03 |
| Food and Beverage | $229 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 10 companies. The companies reported $1,283,341 in research payments for these studies, mostly to the institutions running them.
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06299098 - CT-388-104 OW/OB with T2D
Genentech, Inc. - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with R…
AstraZeneca Pharmaceuticals LP - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - CT-388-104 OW/OB with T2D
F. Hoffmann-la Roche AG - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc. - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.